Twist Bioscience Corporation research snapshot
TWST AI stock analysis reads Twist Bioscience as a high-growth synthetic biology platform with silicon-based DNA writing technology, expanding NGS tools and antibody optimization products, and growing revenue toward potential profitability. At the July 12, 2026 data cutoff, TWST traded near $90.64 with a verified market capitalization near $5.64 billion. The stock has rallied 185% year to date on improving revenue growth and optimism around the synthetic biology mega-trend, but remains pre-profit with a Price/Sales multiple near 13.5x. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$90.64
Market cap
$5.64 billion
AI score
62 / 100
Rating
High-growth synthetic biology platform, pre-profit stage watch
Trend status
Strong uptrend after 185% YTD rally, near 52-week highs with high beta
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Twist manufactures synthetic DNA on silicon at scale for drug discovery, diagnostics, NGS, and research. Customers pay for speed, accuracy, and throughput that traditional methods cannot match. | Medium-high |
| Moat | Moat comes from silicon-based synthesis technology, scaled manufacturing, validated customer workflows, and switching costs in NGS panels and antibody libraries. Competition from IDT, GenScript, and large life science tools firms keeps the moat narrow. | Medium |
| Management | Founder-led with strong scientific credibility. Management has grown revenue consistently, expanded product lines, and built manufacturing scale. Capital allocation prioritizes R&D and capacity over near-term profits. | Medium |
| Financial trend | Revenue grew from $203M in FY2022 to $409M in TTM. Net losses have narrowed but the company remains pre-profit with negative free cash flow of $58M TTM. | Medium-high |
| Valuation | At $90.64, TWST trades at 13.5x TTM revenue and 12.4x book value. The P/S multiple is elevated for a pre-profit company but reflects the synthetic biology growth opportunity and improving revenue trajectory. | Medium |
| Technical trend | Price is in a strong uptrend, well above the 52-week low of $23.30 and approaching the high of $105.47. RSI may be elevated after the YTD rally, suggesting momentum but also pullback risk. | Medium |
| Risk level | Main risks include pre-profit status and cash burn, competition from larger life science tools companies, customer concentration, technology obsolescence, and the high beta (2.12) amplifying downside moves. | Medium-high |
| AI confidence | High for descriptive facts and audited calculations, medium for forward scenarios and chart levels. | High data confidence |
| Investment certainty | Low to medium certainty. The page frames scenarios and monitoring rules, not a buy or sell instruction. | Low to medium |
TWST AI stock forecast
The TWST AI stock forecast uses scenario math around the $90.64 quote and estimated revenue trajectory. The framework produced a bearish area near $45, a base area near $82, and a bullish area near $130, reflecting the wide uncertainty range for a pre-profit growth company.
$120 to $140
More likely if revenue growth accelerates past 25%, operating losses narrow faster than expected, the company reaches GAAP profitability within 12-18 months, and the market maintains a premium multiple on synthetic biology exposure.
$75 to $90
More likely if Twist continues growing revenue around 15-20%, keeps reducing losses at a measured pace, and the P/S multiple compresses toward 10-12x as the initial YTD rally excitement stabilizes.
$40 to $50
More likely if revenue growth slows, cash burn continues without a clear profitability timeline, competition from IDT or Danaher intensifies, or the market rotates away from pre-profit growth stocks.
TWST AI technical analysis
TWST AI technical analysis shows a stock in a powerful uptrend as of the July 12, 2026 data cutoff. The 185% YTD rally has pushed price from the $30 area to near $90, with the 52-week high of $105.47 as the next major resistance. Momentum is strong but elevated, and pullbacks toward moving averages would be expected in any normal consolidation.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $90.64 | Quote snapshots around the July 10, 2026 close placed TWST near $90.64 on the NYSE. |
| Near support | $78 to $82 | The area around previous resistance from early 2026 that may act as support on a pullback. |
| Deeper support | $58 to $62 | The 50-day moving average area, which has provided support during the uptrend. |
| Near resistance | $100 to $105.47 | The 52-week high of $105.47 is the key overhead resistance after the YTD rally. |
| Long-term resistance | $105.47 | The 52-week high serves as the upper reference point for the current trend. |
| Momentum | RSI likely elevated above 60 | After a prolonged rally, RSI is likely in elevated territory, suggesting the trend is strong but extended. |
| Volume | Average volume near 1.8 million shares | Yahoo Finance listed average volume near 1.78 million shares, useful for judging breakout quality. |
| Volatility | Beta of 2.12 | TWST carries a beta of 2.12, meaning it tends to move more than twice the market in either direction. |
| Invalidation | Close below $58 | A decisive close below the 50-day moving average area would weaken the uptrend thesis and suggest a deeper correction. |
TWST AI trading strategy
The TWST AI trading strategy is a rules-based research framework for monitoring a high-growth synthetic biology stock. It is not personal advice and should be paired with fresh chart data, filings, position sizing, and a defined invalidation level.
Watch for TWST to hold above the $78 to $82 support zone, then clear the $100 to $105 area on elevated volume. A sustained move toward new highs would require continued revenue acceleration and optimism around the synthetic biology sector.
A close below $78 or a failed attempt at the 52-week high after the next earnings update should invalidate the near-term momentum setup.
If TWST pulls back toward the $58 to $62 area without a negative fundamental catalyst, monitor for signs of stabilization and volume contraction before considering re-entry.
Do not average down without a maximum loss rule because pre-profit biotech stocks can gap down 15-20% on missed milestones, competitive news, or sector rotation.
Track quarterly revenue growth rates, gross margin trajectory, operating expense trends, cash position, cash runway, and any announcements about new platform applications or strategic partnerships.
Reduce confidence if revenue growth decelerates below 15% year-over-year, cash burn accelerates, or management signals delayed profitability timing.
Investment research summary
Twist Bioscience writes synthetic DNA on silicon wafers. Customers pay because they need custom genes, NGS panels, antibody libraries, and DNA-based tools that are faster, more accurate, and more scalable than traditional synthesis methods.
The moat is technology-based but not absolute. Twists silicon platform offers throughput and cost advantages over column-based methods, and validated workflows create switching costs. However, deep-pocketed competitors such as IDT (Danaher), GenScript, and Agilent can invest to close the gap.
The thesis fails if DNA synthesis remains a commodity service, competitors match Twist technology, revenue growth stalls before reaching profitability, cash burn requires dilutive financing, or the synthetic biology market develops slower than expected.
Founder and CEO Emily Leproust brings strong scientific and operational experience. The management team has executed well on scaling manufacturing and expanding the product portfolio. Key risks include key-person dependence and the challenge of transitioning from growth-at-all-costs to a profitable business model.
Synthetic biology is in a long-term secular growth phase. Declining DNA synthesis costs enable new applications in therapeutics, diagnostics, agriculture, materials, and data storage. Twist is positioned as a leading platform, but the industry remains early-stage and capital-intensive.
At roughly 13.5x TTM revenue, TWST trades at a premium that reflects long-duration synthetic biology optionality and the recent revenue growth trajectory. Margin of safety is limited at current levels, with the stock requiring continued execution and sector enthusiasm to sustain the multiple.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| TWST price | $90.64 | Yahoo Finance quote snapshot | July 12, 2026 |
| Market capitalization | $5.64 billion, verified as $90.64 x 61.70 million shares | financial_rigor.py market cap verification | July 12, 2026 |
| Revenue (TTM) | $409.48 million, cross-checked against third-party sources | Yahoo Finance financials | July 12, 2026 |
| Net income (TTM) | -$81.28 million | Yahoo Finance financials | July 12, 2026 |
| EPS (TTM) | -$1.32 | Yahoo Finance statistics | July 12, 2026 |
| Cash and cash equivalents | $171.67 million | Yahoo Finance balance sheet | July 12, 2026 |
| Free cash flow (TTM) | -$58.48 million | Yahoo Finance cash flow | July 12, 2026 |
| Price to sales ratio | 13.46x TTM revenue | Yahoo Finance statistics | July 12, 2026 |
| Shares outstanding | 61.70 million | CompaniesMarketCap | July 12, 2026 |
| 52-week range | $23.30 to $105.47 | Yahoo Finance statistics | July 12, 2026 |
| Beta | 2.12 | Yahoo Finance statistics | July 12, 2026 |
| Analyst consensus target | $77.70 average, $102 high (Evercore ISI recently raised to $102) | Yahoo Finance analyst estimates | July 12, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell TWST stock. Forecast scenarios are based on available public data, technical snapshots, and stated assumptions as of the data cutoff date and may be wrong. Always verify current filings, prices, risks, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
